Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.68 |
| ▸ | GCGR | P47871 | 4/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10993716 | 0.92 | MAPK14 (0.78) | MAPK14GCGRPTGS2NR4A2MAPK13 | |
| SCHEMBL3424232 | 0.87 | MAPT (0.52) | MAPK14GCGRPTGS2MAPT | |
| SCHEMBL12270293 | 0.83 | MAPT (0.48) | MAPK14GCGRPTGS2MAPTALOX5 | |
| SCHEMBL8145210 | 0.81 | MAPK14 (1.00) | MAPK14GCGRPTGS2MAPK13MAPK12 | |
| SCHEMBL5649479 | 0.81 | MAPK14 (1.00) | MAPK14GCGRPTGS2MAPK13MAPK12 | |
| SCHEMBL8962658 | 0.80 | RPS6KA3 (0.56) | MAPK14GCGRMAPTALOX5 | |
| SCHEMBL12270186 | 0.79 | MAPT (0.44) | MAPK14GCGRPTGS2MAPT | |
| SCHEMBL10971724 | 0.78 | MAPK14 (0.60) | MAPK14GCGRPTGS2MAPK13MAPK12 | |
| Piperazine SCHEMBL28105170 | 0.78 | MAPT (0.44) | MAPK14GCGRPTGS2MAPT | |
| Pyridine SCHEMBL28104888 | 0.76 | MAPK14 (0.58) | MAPK14GCGRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | AZI2, ABL1, RET | MAPK14 818/4885GCGR 1573/4885PTGS2 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.